Tropis® Intradermal Delivery Proves Effective for Self-Amplifying mRNA Vaccines: Nature Study

Innovative needle-free injection technology is revolutionizing the pharmaceutical industry by enhancing the performance and accessibility of vaccines and therapeutics. PharmaJet, a leader in this field, offers solutions that not only improve immunogenicity but also accelerate the time to market for new products. Their needle-free systems, Tropis® ID and Stratis® IM/SC, are designed for intradermal and intramuscular/subcutaneous injections respectively, providing a safe and user-friendly alternative to traditional needle-based injections.

The core benefits of PharmaJet's needle-free technology include improved performance with robust antibody and T-cell responses, which eliminates the need for reformulation. Additionally, the company reduces market entry risks by offering commercialized platforms, comprehensive clearances, and a global manufacturing capacity. This has resulted in a growing list of worldwide partners and a significant increase in user preference and vaccination coverage, supported by data from over 20 countries.

PharmaJet's commitment to making vaccines accessible, safe, and effective in combating global diseases is evident through their WHO PQS certification and CE Mark for various injection methods. The company's partnership model is designed to be straightforward and supportive, beginning with understanding the partner's science and challenges, followed by a customized collaboration plan. This includes sharing experiences and data from numerous development programs to create an efficient timeline.

Expert support is provided throughout the process, from pre-clinical to clinical validation, with technical assistance, product training, and guidance on regulatory compliance. Once initial testing is successful, PharmaJet works with partners to develop a commercialization agreement that aids in study completion, regulatory submissions, and confident market launches.

Globally, PharmaJet has commercial and development partners for vaccines aimed at preventing infectious diseases and treating cancer. Their innovative needle-free injection systems are being utilized in various countries, demonstrating the company's impact on improving access to life-enhancing pharmaceuticals.

The technology has the potential to transform the delivery of vaccines and medicines, offering a more effective and safer method for patients and healthcare providers. By leveraging the body's natural immune response through intradermal injection, PharmaJet's systems can lead to better outcomes and broader acceptance of vaccines, ultimately contributing to improved public health on a global scale.